Julienne L. Carstens

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Sujith Sarvesh · 3 shared papers, 2025–2026 · strength 0.66
   • Paper Antibody subclass deficiency accelerates tumorigenesis in genetically engineered mouse models of pancreatic cancer. DOI 10.1172/jci.insight.198489↗
   • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
2. Jeremy B. Foote · 3 shared papers, 2025–2026 · strength 0.66
   • Paper Antibody subclass deficiency accelerates tumorigenesis in genetically engineered mouse models of pancreatic cancer. DOI 10.1172/jci.insight.198489↗
   • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
3. Raghu Kalluri · 5 shared papers, 2015–2022 · strength 0.46
   • Paper Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis i… DOI 10.1016/j.celrep.2021.108990↗
   • Paper Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resis… DOI 10.1158/2159-8290.cd-20-1484↗
   • Paper Dual reporter genetic mouse models of pancreatic cancer identify an epithelial-to-mesenchymal transition-independent me… DOI 10.15252/emmm.201809085↗
4. Ashiq Masood · 2 shared papers, 2025–2026 · strength 0.45
   • Paper Conserved Metastatic Cell States and Spatial Immune Microenvironment Remodeling Define Pancreatic Cancer Liver Metastas… DOI 10.64898/2026.05.27.728281↗
   • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
5. Upender Manne · 2 shared papers, 2025 · strength 0.38
   • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
6. Dhana Sekhar Reddy Bandi · 2 shared papers, 2025 · strength 0.38
   • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
7. Karina Jin Yoon · 2 shared papers, 2025 · strength 0.38
   • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
8. Ganji Purnachandra Nagaraju · 2 shared papers, 2025 · strength 0.38
   • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
9. Mehmet Akce · 2 shared papers, 2025 · strength 0.38
   • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
   • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
10. Bassel F. El‐Rayes · 2 shared papers, 2025 · strength 0.38
    • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
    • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
11. Christopher Klug · 1 shared paper, 2026 · strength 0.28
    • Paper Antibody subclass deficiency accelerates tumorigenesis in genetically engineered mouse models of pancreatic cancer. DOI 10.1172/jci.insight.198489↗
12. Xiaofeng Zheng · 3 shared papers, 2015–2021 · strength 0.26
    • Paper Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis i… DOI 10.1016/j.celrep.2021.108990↗
    • Paper Dual reporter genetic mouse models of pancreatic cancer identify an epithelial-to-mesenchymal transition-independent me… DOI 10.15252/emmm.201809085↗
    • Paper Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. DOI 10.1038/nature16064↗
13. Kathleen M. McAndrews · 2 shared papers, 2021–2022 · strength 0.26
    • Paper Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis i… DOI 10.1016/j.celrep.2021.108990↗
    • Paper Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resis… DOI 10.1158/2159-8290.cd-20-1484↗
14. Ayushi Mandloi · 1 shared paper, 2026 · strength 0.26
    • Paper Conserved Metastatic Cell States and Spatial Immune Microenvironment Remodeling Define Pancreatic Cancer Liver Metastas… DOI 10.64898/2026.05.27.728281↗
15. Sujuan Yang · 2 shared papers, 2021–2022 · strength 0.26
    • Paper Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis i… DOI 10.1016/j.celrep.2021.108990↗
    • Paper Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resis… DOI 10.1158/2159-8290.cd-20-1484↗
16. Yang Chen · 2 shared papers, 2018–2022 · strength 0.21
    • Paper Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resis… DOI 10.1158/2159-8290.cd-20-1484↗
    • Paper Dual reporter genetic mouse models of pancreatic cancer identify an epithelial-to-mesenchymal transition-independent me… DOI 10.15252/emmm.201809085↗
17. Yuvasri Golivi · 1 shared paper, 2025 · strength 0.19
    • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
18. Cameron J. Herting · 1 shared paper, 2025 · strength 0.19
    • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
19. Olatunji Boladale Alese · 1 shared paper, 2025 · strength 0.19
    • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
20. Manoj Bhasin · 1 shared paper, 2025 · strength 0.19
    • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
21. Gregory B. Lesinski · 1 shared paper, 2025 · strength 0.19
    • Paper Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroqui… DOI 10.1016/j.xcrm.2024.101881↗
22. Yulia Y. Maxuitenko · 1 shared paper, 2025 · strength 0.19
    • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
23. Donald J Buchsbaum · 1 shared paper, 2025 · strength 0.19
    • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
24. Adam B. Keeton · 1 shared paper, 2025 · strength 0.19
    • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗
25. Gary Anthony Piazza · 1 shared paper, 2025 · strength 0.19
    • Paper ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic d… DOI 10.1186/s12943-025-02288-9↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.